Get More Information on Antidepressants Market - Request Sample Report
The Antidepressants Market Size was valued at USD 19.92 Billion in 2023, and is expected to reach USD 37.44 Billion by 2032, and grow at a CAGR of 7.66%.
The rising prevalence of depression is attributed to increased awareness and understanding of the disorder. There has been a significant global effort to educate the public and healthcare professionals about mental health, reduce stigma, and encourage early diagnosis and treatment. Organizations such as the World Health Organization (WHO) and various national health bodies have played crucial roles in this awareness campaign. As a result, more individuals are seeking help and being diagnosed, contributing to the observed rise in reported cases of depression. This heightened awareness is leading to more people being identified with depression, who might otherwise have gone untreated. For instance, the WHO reported in September 2021 that approximately 5.0% of adults globally experienced one or more depressive episodes in their lifetime.
The pharmaceutical industry has seen significant advancements in the development of novel biologics, which are contributing to the growth of the antidepressant market. Biologics, including monoclonal antibodies and gene therapies, represent a new frontier in the treatment of depression. These innovative treatments are designed to target specific pathways involved in depression, offering potentially more effective and personalized options compared to traditional medications. The development of biologics has been accelerated by advances in biotechnology and an improved understanding of the neurobiological mechanisms underlying depression. For example, drugs like ketamine and its derivatives, which work differently from conventional antidepressants, have shown promising results in treating treatment-resistant depression. This expansion in treatment options is expected to drive market growth as patients and healthcare providers seek out the most effective therapies.
|
Country |
Phone Number |
|
United States |
+1-800-273-8255 (988) |
|
Canada |
+1-866-387-2273 |
|
Mexico |
+52-800-011-1000 |
|
United Kingdom |
+44-116-123 |
|
France |
+33-0-800-13-0000 |
|
Germany |
+49-0800-11-13-14 |
|
Spain |
+34-91-717-00-11 |
|
Italy |
+39-199-696-969 |
|
Russia |
+7-8-800-100-75-03 |
|
India |
+91-91-9999-666-555 |
|
China |
+86-800-810-1117 |
|
Japan |
+81-03-5773-3696 |
|
South Korea |
+82-1399 |
|
Australia |
+61-13-11-14 |
|
South Africa |
+27-0800-21-1702 |
In economically developed countries like the UK and the US, the prevalence of depression is particularly notable. Rapid economic changes and high-stress environments contribute to mental health challenges, with many individuals experiencing depression across various age groups. For instance, data from the Anxiety and Depression Foundation of America in January 2022 indicated that around 6.8 million adults in the US, or approximately 3.1% of the population, are affected by generalized anxiety disorder annually. The high prevalence of these conditions in developed countries drives a substantial demand for antidepressant medications. The combination of increased awareness, the development of novel biologics, and the high disease burden contribute to a growing global market for antidepressants. As more individuals are diagnosed and seek effective treatments, the demand for antidepressants is expected to rise.
Key Drivers:
Increasing Number of Cases of Depression Around the World is Propelling the Growth of the Market.
Increasing Awareness of Depression is Fueling the Growth of the Market.
Restraints:
Preference of Non-pharmacological Therapies over Pharmacological Therapies Pose a Significant Barrier to Market Growth.
Side Effects and Patent Expiry of Antidepressant Drugs are expected to Hamper the Growth of the Market.
Opportunity:
Development of Novel Antidepressant Classes Opens Up Significant Opportunities in Antidepressants Market.
Expansion of Digital Therapeutics and Telemedicine Integration Present Substantial Growth Opportunities.
By Drug Class
In 2023, Selective Serotonin Reuptake Inhibitors (SSRIs) dominated the antidepressant market, accounting for approximately 45% of total sales. SSRIs are the most commonly prescribed antidepressants and are considered the primary treatment for major depressive disorder and anxiety-related conditions. According to the United States Food and Drug Administration (US FDA) guidelines, SSRIs are the first-line treatment for depression. Following the COVID-19 pandemic, there has been an increase in the prescription of SSRIs worldwide due to a surge in anxiety and depressive disorders. In Europe, the European Medicines Agency (EMA) reported a 12% increase in SSRI sales in 2023. SSRIs will likely continue to be the dominant class of drugs in the antidepressant market due to their affordability, wide availability, and effectiveness, particularly with the entrance of more generic options into the market.
By Distribution Channel
In 2023, hospital pharmacies held the largest market share and are expected to have a higher-than-average Compound Annual Growth Rate (CAGR) of around 55% among distribution channels. This increase is largely due to more frequent visits by both inpatients and outpatients for mental health prescription drugs through hospital pharmacies. Hospital admissions related to mental health conditions have increased by 25%, leading to a rise in the dispensing of antidepressants via hospital pharmacies.
This trend is exacerbated by individuals who have had little contact with the mental health system and present in severe distress, leading to higher antidepressant prescriptions through these sites. Factors such as the expansion of psychiatric units and government policies aimed at improving mental health services are also contributing to the greater footprint of hospital pharmacies in this market.
The retail pharmacy sector had a smaller market share of around 30%, with increased accessibility and convenience, but it is rapidly growing. Online pharmacies, constituting almost 15% of the market, have been driven by telemedicine and online prescription services, especially during the pandemic.
In 2023, North America led the market for antidepressants, holding a substantial global market share of about 40%. The United States, in particular, contributed to this leadership position due to the prevalence of mental health disorders and a well-resourced healthcare system. Statistics from the U.S. Centers for Disease Control and Prevention (CDC) estimated that about 17.3 million American adults suffered from a major depressive episode in 2023, creating an environment conducive to pharmaceutical treatment with antidepressants. Additionally, around 13.4% of American adults were reported to have been using antidepressants in that year.
This dominance is further bolstered by significant government interest and investment in mental health programs. Notably, the United States allocated USD 1.5 billion of federal monies for mental health services funding for 2023 alone. North America's sophisticated pharmaceutical industry and key market players like Pfizer and Eli Lilly make it easy for affected patients to access various antidepressant medications.
Following North America, the European market held a share of almost 30%, driven by factors such as health policies and steadily rising public acknowledgment of developments in mental health treatment. Government-backed campaigns in countries like the UK and Germany have resulted in significant increases in diagnoses and treatment for mental health conditions.
Need any customization research on Antidepressants Market - Enquiry Now
The players operating in the antidepressant market are the following:
Pfizer: Zoloft (sertraline), Effexor XR (venlafaxine), Pristiq (desvenlafaxine)
Eli Lilly and Company: Prozac (fluoxetine), Cymbalta (duloxetine)
GlaxoSmithKline: Paxil (paroxetine), Wellbutrin (bupropion)
Johnson & Johnson: Remeron (mirtazapine)
AbbVie: Trintellix (vortioxetine)
Lundbeck: Abilify (aripiprazole)
AstraZeneca: Seroquel (quetiapine)
Merck & Co., Inc.: Remicade (infliximab)
Takeda: Vyvanse (lisdexamfetamine)
Janssen Pharmaceuticals: Risperdal (risperidone)
Novartis: Trileptal (oxcarbazepine)
Sandoz: generic
Teva Pharmaceuticals: generic
Mylan: generic
Sun Pharmaceutical Industries: generic
Aurobindo Pharma: generic
Dr. Reddy's Laboratories: generic
Intas Pharmaceuticals: generic
Glenmark Pharmaceuticals: generic
Cipla: generic
In August 2022, the U.S. FDA approved dextromethorphan-bupropion (Auvelity, Axsome Therapeutics) for the treatment of major depressive disorder in adults. It is the only medication that takes effect within 7 days of intake.
In April 2022, a study showed that vortioxetine, available under the brand names Trintellix or Brintellix, was more effective in treating major depressive disorder (MDD) compared to desvenlafaxine, which is the active ingredient in Pfizer's anti-depression drug Pristiq.
| Report Attributes | Details |
|---|---|
|
Market Size in 2023 |
US$ 19.92 Billion |
|
Market Size by 2032 |
US$ 37.44 Billion |
|
CAGR |
CAGR of 7.66% From 2024 to 2032 |
|
Base Year |
2023 |
|
Forecast Period |
2024-2032 |
|
Historical Data |
2020-2022 |
|
Report Scope & Coverage |
Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook |
|
Key Segments |
•By Drug Class (Selective Serotonin Reuptake Inhibitors, Serotonin & Norepinephrine Reuptake Inhibitors, Atypical Antidepressants, Tricyclic Antidepressants, Monoamine Oxidase Inhibitors (MAOIs) & Others) |
|
Regional Analysis/Coverage |
North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America) |
|
Company Profiles |
GlaxoSmithKline PLC, AbbiVe Inc., Sun Pharmaceuticals Pvt. Ltd, Eli Lilly and Company, Johnson & Johnson, Pfizer Inc., Merck & Co. Inc., Sanofi, AstraZeneca, Dr. Reddy's Laboratories, H. Lundbeck AS & Other players |
|
Key Drivers |
•Increasing Number of Cases of Depression Around the World is Propelling the Growth of the Market |
|
RESTRAINTS |
•Preference of Non-pharmacological Therapies over Pharmacological Therapies Pose a Significant Barrier to Market Growth. |
Ans: The Antidepressants Market is expected to grow at a CAGR of 7.66%.
Ans: The Antidepressants Market size is expected to Reach USD 37.44 billion by 2032.
Ans: The increasing prevalence of mental illness and the availability of specialist facilities are significant factors driving the antidepressant industry. Furthermore, yearly medication introductions and advancements in therapy are two important drivers driving market development.
Ans: Many antidepressant medications have reached or will soon reach the end of their patent protection, leading to the entry of generic versions into the market. Generic competition can result in price erosion and reduced profit margins for pharmaceutical companies, as generic versions are typically priced lower than branded medications.
Ans: North America will emerge as the prominent region, accounting for 38% of the worldwide market share.
Table of Contents
1. Introduction
1.1 Market Definition
1.2 Scope (Inclusion and Exclusions)
1.3 Research Assumptions
2. Executive Summary
2.1 Market Overview
2.2 Regional Synopsis
2.3 Competitive Summary
3. Research Methodology
3.1 Top-Down Approach
3.2 Bottom-up Approach
3.3. Data Validation
3.4 Primary Interviews
4. Market Dynamics Impact Analysis
4.1 Market Driving Factors Analysis
4.1.1 Drivers
4.1.2 Restraints
4.1.3 Opportunities
4.1.4 Challenges
4.2 PESTLE Analysis
4.3 Porter’s Five Forces Model
5. Statistical Insights and Trends Reporting
5.1 Incidence and Prevalence (2023)
5.2 Prescription Trends, (2023), by Region
5.3 Drugs Volume: Drug Class and usage volumes of pharmaceuticals.
5.4 Healthcare Spending: Expenditure data by government, insurers, and out-of-pocket by patients
6. Competitive Landscape
6.1 List of Major Companies, By Region
6.2 Market Share Analysis, By Region
6.3 Drug Class Benchmarking
6.3.1 Drug Class specifications and features
6.3.2 Pricing
6.4 Strategic Initiatives
6.4.1 Marketing and promotional activities
6.4.2 Distribution and Supply Chain Strategies
6.4.3 Expansion plans and new Drug Class launches
6.4.4 Strategic partnerships and collaborations
6.5 Technological Advancements
6.6 Market Positioning and Branding
7. Antidepressants Market Segmentation, by Drug Class
7.1 Chapter Overview
7.2 Selective Serotonin Reuptake Inhibitors (SSRIs)
7.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Trends Analysis (2020-2032)
7.2.2 Selective Serotonin Reuptake Inhibitors (SSRIs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.3 Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
7.3.1 Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) Market Trends Analysis (2020-2032)
7.3.2 Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.4 Atypical Antidepressants
7.4.1 Atypical Antidepressants Market Trends Analysis (2020-2032)
7.4.2 Atypical Antidepressants Market Size Estimates and Forecasts to 2032 (USD Billion)
7.5 Tricyclic Antidepressants (TCAs)
7.5.1 Tricyclic Antidepressants (TCAs) Market Trends Analysis (2020-2032)
7.5.2 Tricyclic Antidepressants (TCAs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.6 Monoamine Oxidase Inhibitors (MAOIs)
7.6.1 Monoamine Oxidase Inhibitors (MAOIs) Market Trends Analysis (2020-2032)
7.6.2 Monoamine Oxidase Inhibitors (MAOIs) Market Size Estimates and Forecasts to 2032 (USD Billion)
7.7 Others
7.7.1 Others Market Trends Analysis (2020-2032)
7.7.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
8. Antidepressants Market Segmentation, by Disorder
8.1 Chapter Overview
8.2 Major Depressive Disorder
8.2.1 Major Depressive Disorder Market Trends Analysis (2020-2032)
8.2.2 Major Depressive Disorder Market Size Estimates and Forecasts to 2032 (USD Billion)
8.3 Obsessive Compulsive Disorder
8.3.1 Obsessive Compulsive Disorder Market Trends Analysis (2020-2032)
8.3.2 Obsessive Compulsive Disorder Market Size Estimates and Forecasts to 2032 (USD Billion)
8.4 Generalized Anxiety Disorder
8.4.1 Generalized Anxiety Disorder Market Trends Analysis (2020-2032)
8.4.2 Generalized Anxiety Disorder Market Size Estimates and Forecasts to 2032 (USD Billion)
8.5 Panic Disorder
8.5.1 Panic Disorder Market Trends Analysis (2020-2032)
8.5.2 Panic Disorder Market Size Estimates and Forecasts to 2032 (USD Billion)
8.6 Others
8.6.1 Others Market Trends Analysis (2020-2032)
8.6.2 Others Market Size Estimates and Forecasts to 2032 (USD Billion)
9. Antidepressants Market Segmentation, by Distribution Channel
9.1 Chapter Overview
9.2 Hospital Pharmacy
9.2.1 Hospital Pharmacy Market Trends Analysis (2020-2032)
9.2.2 Hospital Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.3 Retail Pharmacy
9.3.1 Retail Pharmacy Market Trends Analysis (2020-2032)
9.3.2 Retail Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
9.4 Online Pharmacy
9.4.1 Online Pharmacy Market Trends Analysis (2020-2032)
9.4.2 Online Pharmacy Market Size Estimates and Forecasts to 2032 (USD Billion)
10. Regional Analysis
10.1 Chapter Overview
10.2 North America
10.2.1 Trends Analysis
10.2.2 North America Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.2.3 North America Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.4 North America Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.2.5 North America Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.6 USA
10.2.6.1 USA Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.6.2 USA Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.2.6.3 USA Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.7 Canada
10.2.7.1 Canada Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.7.2 Canada Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.2.7.3 Canada Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.2.8 Mexico
10.2.8.1 Mexico Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.2.8.2 Mexico Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.2.8.3 Mexico Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3 Europe
10.3.1 Eastern Europe
10.3.1.1 Trends Analysis
10.3.1.2 Eastern Europe Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.1.3 Eastern Europe Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.4 Eastern Europe Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.1.5 Eastern Europe Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.6 Poland
10.3.1.6.1 Poland Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.6.2 Poland Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.1.6.3 Poland Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.7 Romania
10.3.1.7.1 Romania Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.7.2 Romania Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.1.7.3 Romania Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.8 Hungary
10.3.1.8.1 Hungary Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.8.2 Hungary Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.1.8.3 Hungary Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.9 Turkey
10.3.1.9.1 Turkey Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.9.2 Turkey Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.1.9.3 Turkey Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.1.10 Rest of Eastern Europe
10.3.1.10.1 Rest of Eastern Europe Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.1.10.2 Rest of Eastern Europe Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.1.10.3 Rest of Eastern Europe Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2 Western Europe
10.3.2.1 Trends Analysis
10.3.2.2 Western Europe Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.3.2.3 Western Europe Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.4 Western Europe Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.5 Western Europe Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.6 Germany
10.3.2.6.1 Germany Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.6.2 Germany Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.6.3 Germany Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.7 France
10.3.2.7.1 France Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.7.2 France Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.7.3 France Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.8 UK
10.3.2.8.1 UK Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.8.2 UK Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.8.3 UK Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.9 Italy
10.3.2.9.1 Italy Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.9.2 Italy Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.9.3 Italy Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.10 Spain
10.3.2.10.1 Spain Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.10.2 Spain Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.10.3 Spain Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.11 Netherlands
10.3.2.11.1 Netherlands Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.11.2 Netherlands Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.11.3 Netherlands Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.12 Switzerland
10.3.2.12.1 Switzerland Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.12.2 Switzerland Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.12.3 Switzerland Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.13 Austria
10.3.2.13.1 Austria Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.13.2 Austria Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.13.3 Austria Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.3.2.14 Rest of Western Europe
10.3.2.14.1 Rest of Western Europe Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.3.2.14.2 Rest of Western Europe Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.3.2.14.3 Rest of Western Europe Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4 Asia Pacific
10.4.1 Trends Analysis
10.4.2 Asia Pacific Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.4.3 Asia Pacific Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.4 Asia Pacific Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.5 Asia Pacific Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.6 China
10.4.6.1 China Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.6.2 China Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.6.3 China Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.7 India
10.4.7.1 India Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.7.2 India Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.7.3 India Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.8 Japan
10.4.8.1 Japan Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.8.2 Japan Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.8.3 Japan Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.9 South Korea
10.4.9.1 South Korea Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.9.2 South Korea Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.9.3 South Korea Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.10 Vietnam
10.4.10.1 Vietnam Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.10.2 Vietnam Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.10.3 Vietnam Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.11 Singapore
10.4.11.1 Singapore Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.11.2 Singapore Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.11.3 Singapore Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.12 Australia
10.4.12.1 Australia Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.12.2 Australia Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.12.3 Australia Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.4.13 Rest of Asia Pacific
10.4.13.1 Rest of Asia Pacific Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.4.13.2 Rest of Asia Pacific Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.4.13.3 Rest of Asia Pacific Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5 Middle East and Africa
10.5.1 Middle East
10.5.1.1 Trends Analysis
10.5.1.2 Middle East Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.1.3 Middle East Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.4 Middle East Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.1.5 Middle East Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.6 UAE
10.5.1.6.1 UAE Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.6.2 UAE Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.1.6.3 UAE Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.7 Egypt
10.5.1.7.1 Egypt Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.7.2 Egypt Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.1.7.3 Egypt Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.8 Saudi Arabia
10.5.1.8.1 Saudi Arabia Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.8.2 Saudi Arabia Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.1.8.3 Saudi Arabia Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.9 Qatar
10.5.1.9.1 Qatar Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.9.2 Qatar Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.1.9.3 Qatar Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.1.10 Rest of Middle East
10.5.1.10.1 Rest of Middle East Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.1.10.2 Rest of Middle East Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.1.10.3 Rest of Middle East Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2 Africa
10.5.2.1 Trends Analysis
10.5.2.2 Africa Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.5.2.3 Africa Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.4 Africa Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.2.5 Africa Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.6 South Africa
10.5.2.6.1 South Africa Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.6.2 South Africa Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.2.6.3 South Africa Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.7 Nigeria
10.5.2.7.1 Nigeria Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.7.2 Nigeria Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.2.7.3 Nigeria Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.5.2.8 Rest of Africa
10.5.2.8.1 Rest of Africa Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.5.2.8.2 Rest of Africa Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.5.2.8.3 Rest of Africa Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6 Latin America
10.6.1 Trends Analysis
10.6.2 Latin America Antidepressants Market Estimates and Forecasts, by Country (2020-2032) (USD Billion)
10.6.3 Latin America Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.4 Latin America Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.6.5 Latin America Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.6 Brazil
10.6.6.1 Brazil Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.6.2 Brazil Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.6.6.3 Brazil Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.7 Argentina
10.6.7.1 Argentina Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.7.2 Argentina Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.6.7.3 Argentina Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.8 Colombia
10.6.8.1 Colombia Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.8.2 Colombia Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.6.8.3 Colombia Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
10.6.9 Rest of Latin America
10.6.9.1 Rest of Latin America Antidepressants Market Estimates and Forecasts, by Drug Class (2020-2032) (USD Billion)
10.6.9.2 Rest of Latin America Antidepressants Market Estimates and Forecasts, by Disorder (2020-2032) (USD Billion)
10.6.9.3 Rest of Latin America Antidepressants Market Estimates and Forecasts, by Distribution Channel (2020-2032) (USD Billion)
11. Company Profiles
11.1 GlaxoSmithKline PLC
11.1.1 Company Overview
11.1.2 Financial
11.1.3 Drug Class/ Services Offered
11.1.4 SWOT Analysis
11.2 AbbiVe Inc.
11.2.1 Company Overview
11.2.2 Financial
11.2.3 Drug Class/ Services Offered
11.2.4 SWOT Analysis
11.3 Sun Pharmaceuticals Pvt. Ltd
11.3.1 Company Overview
11.3.2 Financial
11.3.3 Drug Class/ Services Offered
11.3.4 SWOT Analysis
11.4 Eli Lilly and Company
11.4.1 Company Overview
11.4.2 Financial
11.4.3 Drug Class/ Services Offered
11.4.4 SWOT Analysis
11.5 Johnson & Johnson
11.5.1 Company Overview
11.5.2 Financial
11.5.3 Drug Class/ Services Offered
11.5.4 SWOT Analysis
11.6 Pfizer Inc.
11.6.1 Company Overview
11.6.2 Financial
11.6.3 Drug Class/ Services Offered
11.6.4 SWOT Analysis
11.7 Merck & Co. Inc.
11.7.1 Company Overview
11.7.2 Financial
11.7.3 Drug Class/ Services Offered
11.7.4 SWOT Analysis
11.8 Sanofi
11.8.1 Company Overview
11.8.2 Financial
11.8.3 Drug Class/ Services Offered
11.8.4 SWOT Analysis
11.9 AstraZeneca
11.9.1 Company Overview
11.9.2 Financial
11.9.3 Drug Class/ Services Offered
11.9.4 SWOT Analysis
11.10 Dr. Reddy's Laboratories
11.10.1 Company Overview
11.10.2 Financial
11.10.3 Drug Class/ Services Offered
11.10.4 SWOT Analysis
12. Use Cases and Best Practices
13. Conclusion
An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.
Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.
The 5 steps process:
Step 1: Secondary Research:
Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.
Step 2: Primary Research
When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.
We at SNS Insider have divided Primary Research into 2 parts.
Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.
This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.
Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.
Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.
Step 3: Data Bank Validation
Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.
Step 4: QA/QC Process
After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.
Step 5: Final QC/QA Process:
This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.
Key Segments
By Drug Class
Selective Serotonin Reuptake Inhibitors (SSRIs)
Serotonin and Norepinephrine Reuptake Inhibitors (SNRIs)
Atypical Antidepressants
Tricyclic Antidepressants (TCAs)
Monoamine Oxidase Inhibitors (MAOIs)
Others
By Disorder
Major Depressive Disorder
Obsessive Compulsive Disorder
Generalized Anxiety Disorder
Panic Disorder
Others
By Distribution Channel
Hospital Pharmacy
Retail Pharmacy
Online Pharmacy
Request for Segment Customization as per your Business Requirement: Segment Customization Request
Regional Coverage:
North America
US
Canada
Mexico
Europe
Eastern Europe
Poland
Romania
Hungary
Turkey
Rest of Eastern Europe
Western Europe
Germany
France
UK
Italy
Spain
Netherlands
Switzerland
Austria
Rest of Western Europe
Asia Pacific
China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific
Middle East & Africa
Middle East
UAE
Egypt
Saudi Arabia
Qatar
Rest of the Middle East
Africa
Nigeria
South Africa
Rest of Africa
Latin America
Brazil
Argentina
Colombia
Rest of Latin America
Request for Country Level Research Report: Country Level Customization Request
Available Customization
With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:
Product Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Product Matrix which gives a detailed comparison of the product portfolio of each company
Geographic Analysis
Additional countries in any of the regions
Company Information
Detailed analysis and profiling of additional market players (Up to five)
The Skin Cancer Treatment Market Size was valued at USD 10.98 Billion in 2023 and is expected to reach USD 20.74 Billion by 2032 and grow at a CAGR of 7.66% over the forecast period 2024-2032.
The Healthcare Automation Market size was valued at USD 46.54 billion in 2023 and is expected to reach USD 86.71 billion by 2031 and grow at a CAGR of 8.11% over the forecast period of 2024-2031.
The Ureteroscope Market Size was valued at USD 1,056.2 Million in 2023 and is expected to reach USD 1,685.14 Million by 2032 and grow at a CAGR of 5.54% over the forecast period 2024-2032.
The Advanced Visualization Market was valued at USD 3.64 Billion in 2023 and it is projected to reach USD 9.77 Billion by 2032, registering a compound annual growth rate (CAGR) of 11.6% from 2024 to 2032.
The Drug Addiction Treatment Market size was estimated at USD 18.81 billion in 2023 and is expected to reach USD 33.17 billion by 2031 at a CAGR of 7.35% during the forecast period of 2024-2031.
The Women’s Health Therapeutics Market Size was valued at USD 43.21 Bn in 2023 & will reach to USD 61.6 Bn by 2032 & grow at a CAGR of 4.05% by 2024-2032.
Hi! Click one of our member below to chat on Phone
© 2024 All Rights Reserved by SNS Insider Pvt Ltd
